Entasis Therapeutics Holdings Inc. (ETTX) Prices 5M Share IPO at $15/Sh

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that it has priced its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. The gross proceeds to Entasis, before deducting underwriting discounts, commissions and offering expenses, are expected to be approximately $75 million. All of the common stock is being offered by Entasis. In addition, Entasis has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock to cover over-allotments, if any, at the initial public offering price, less the underwriting discounts and commissions.

The common stock is expected to begin trading on The Nasdaq Global Market on September 26, 2018 under the trading symbol "ETTX." The offering is expected to close on September 28, 2018, subject to customary closing conditions.

Credit Suisse and BMO Capital Markets are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey and Wedbush PacGrow are also acting as co-managers for the offering.

You May Also Be Interested In

• Ives Ultra AI Opportunities prices $200M IPO on NYSE
• Exclusive-Tiger Global, Dragoneer in talks to invest in Kalshi's new $1 billion fundraise, sources say
• Oura postpones Nasdaq IPO, citing market uncertainty